Newsroom | 44469 results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Orthofix will participate in the following investor conferences: Goldman Sachs 47th Annual Global Healthcare Conference - Miami Beach, June 8, 2026, Fireside Chat Time: 8:40 am Eastern Time Truist Securities MedTech Conference - Boston, June 16, 2026, 1x1 Meetings Only Interested parties can access the live and archived webcast of the Goldman Sachs fireside...

SANTA CLARA, Calif.--(BUSINESS WIRE)--VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 millio...

JERSEY CITY, N.J.--(BUSINESS WIRE)--A Organon (NYSE: OGN), empresa global de saúde com a missão de oferecer medicamentos e soluções de impacto para um dia a dia mais saudável, apresentará dados nas áreas de saúde feminina, biossimilares, dermatologia e neurologia no ISPOR 2026, a principal conferência científica global promovida pela International Society for Pharmacoeconomics and Outcomes Research. A conferência, focada em economia da saúde e pesquisa de desfechos, ocorrerá de 17 a 20 de maio...

紐澤西州澤西市--(BUSINESS WIRE)--(美國商業資訊)-- 全球性醫療保健公司Organon (NYSE: OGN)致力於提供具有影響力的藥物和解決方案，以守護大眾日常健康。公司將在國際藥物經濟學與結果研究協會主辦的全球頂尖學術會議ISPOR 2026上發表涵蓋女性健康、生物相似藥、皮膚病學和神經病學領域的多項研究資料。本次大會聚焦衛生經濟學與結果研究，將於2026年5月17日至20日在賓夕法尼亞州費城舉行。 本次共有8篇摘要入選大會展示，相關資料體現Organon致力於立足真實生活經驗生成真實世界證據，可為醫療決策制定提供參考，並改善多個治療領域的健康結果。 Organon研發負責人兼醫療長Juan Camilo Arjona Ferreira, MD表示：「衛生經濟學和結果研究對於確保合適的治療方案嘉惠病患、以及醫療體系長期維持這一服務模式至關重要。在ISPOR 2026上，Organon很榮幸分享關於避孕、皮膚病及神經疾病治療的預算影響、轉診模式和真實世界證據的研究成果，所有研究均以實證為基礎，將病患和醫療執業者視角置於核心位置。」 Organon產品組合將展示的關...

NEW YORK--(BUSINESS WIRE)--AV Laboratories, the science-backed skincare brand redefining the intersection of science, skincare, and longevity, will host an exclusive virtual salon suite on Thursday, May 21, 2026 at 11:00 AM EST for editors, media, and industry insiders. The 30-minute informational session will explore the next frontier of skincare innovation, highlighting the scientific discoveries and advanced research philosophies that inspired AVL’s development and are reshaping the industry...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s Investigational New Drug application to proceed with a clinical study of its investigational UHeart™ derived from a pig with 10 gene edits. The study, known as EXPRESS, will enroll an initial cohort of up to two participants. United Therapeutics...

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) expects to release its financial results for the quarter and fiscal year ended March 31, 2026 before financial markets open on June 15, 2026. The Company also announced it plans to file restated financial results for the fiscal years ended March 31, 2025 and March 31, 2024 and to certain of the interim periods therein (the “Refiling”), in conjunction with its filing of...

BONITA SPRINGS, Fla.--(BUSINESS WIRE)--Optivate, a leading provider of specialty-built software and solutions for ophthalmology practices, today announced the appointment of Brad Caldwell as Chief Executive Officer. Abdiel Marin, the company’s Founder and CEO, will transition to a role as an advisor and remain on the Board of Directors as the company enters its next phase of growth. Caldwell brings extensive experience in healthcare technology, go-to-market strategy, and operational leadership....

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), un'azienda farmaceutica globale con la missione di fornire farmaci e soluzioni efficaci per una vita quotidiana più sana, presenterà dati relativi alla salute delle donne, ai biosimilari, alla dermatologia e alla neurologia in occasione di ISPOR 2026, il principale convegno scientifico mondiale organizzato dalla Società Internazionale di Farmacoeconomia e Ricerca sui Risultati. La conferenza, incentrata sull'economia sanitaria e la ricerc...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), een wereldwijd actief gezondheidszorgbedrijf met als missie het leveren van effectieve geneesmiddelen en oplossingen voor een gezonder dagelijks leven, presenteert gegevens over vrouwengezondheid, biosimilars, dermatologie en neurologie op ISPOR 2026, de toonaangevende internationale wetenschappelijke conferentie van de International Society for Pharmacoeconomics and Outcomes Research. De conferentie, gericht op gezondheidseconomie en uit...